Establishing Preclinical Quantitative Parameters for Future Assessment of Corneal and Retinal Therapeutics for Aniridia
Investigative Ophthalmology & Visual Science · 2025
DOI: 10.1167/iovs.66.9.60 ↗Kurz gefasst
Fachartikel in der Zeitschrift Investigative Ophthalmology & Visual Science, 2025. Verfasst von Sif G Kaad und 2 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Molecular Medicine and Therapeutics at BC Children's Hospital, The University of British Columbia, Vancouver, British Columbia, Canada. Hauptthemen laut MEDLINE: Aniridia, Retina, Cornea. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Centre for Molecular Medicine and Therapeutics at BC Children's Hospital, The University of British Columbia, Vancouver, British Columbia, Canada.
- Department of Medical Genetics, The University of British Columbia, Vancouver, British Columbia, Canada.
- Department of Ophthalmology & Visual Sciences, The University of British Columbia, Vancouver, British Columbia, Canada.
Zitieren
APA
Kaad, S. G., Korecki, A. J., & Simpson, E. M. (2025). Establishing Preclinical Quantitative Parameters for Future Assessment of Corneal and Retinal Therapeutics for Aniridia. Investigative Ophthalmology & Visual Science. https://doi.org/10.1167/iovs.66.9.60
Vancouver
Kaad SG, Korecki AJ, Simpson EM. Establishing Preclinical Quantitative Parameters for Future Assessment of Corneal and Retinal Therapeutics for Aniridia. Investigative Ophthalmology & Visual Science. 2025. doi:10.1167/iovs.66.9.60
BibTeX
@article{Kaad2025,
author = {Kaad, Sif G and Korecki, Andrea J and Simpson, Elizabeth M},
title = {Establishing Preclinical Quantitative Parameters for Future Assessment of Corneal and Retinal Therapeutics for Aniridia},
journal = {Investigative Ophthalmology & Visual Science},
year = {2025},
doi = {10.1167/iovs.66.9.60}
}
EUVIMED